Middle East and Africa Liver Disease Treatment Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Middle East and Africa Liver Disease Treatment Market is segmented By Treatment Type (Antiviral Drugs, Immunosuppressants, Vaccines, Immunoglobulins, Corticosteroids, Targeted Therapy, Chemotherapy Drugs), By Disease Type (Hepatitis, Autoimmune Diseases, Non-Alcoholic Fatty Liver Disease, Liver Cancer, Genetic Disorder, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgery Centers, Others) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The Middle East and Africa liver disease treatment market reached US$ 981.74 million in 2023 and is expected to reach US$ 1,525.63 million by 2031, growing at a CAGR of 5.8% during the forecast period 2024-2031.

The liver disease treatment market is expanding rapidly, driven by the increasing prevalence of liver disorders such as hepatitis, fatty liver disease, and cirrhosis. Factors such as rising alcohol intake, obesity rates, and viral infections all contribute to this trend, creating a greater need for appropriate treatment solutions. The industry offers a wide range of medicines, including antiviral drugs, immunosuppressants, and new gene therapies.

Recent advances in biotechnology and pharmaceuticals have fueled innovation, with many corporations investing in research and development of new medications. This includes medications that target specific pathways involved in liver disease progression, which raises the prospect of more tailored and effective treatments. Furthermore, the growing focus on preventative interventions and early diagnosis is altering market dynamics, with healthcare providers increasingly.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Increasing prevalence of liver diseases 

The rising prevalence of liver diseases propels the market growth. For instance, according to the Journal of Hepatology, Africa has among the highest incidence and mortality rates from liver disease in the world due to the high prevalence of HBV and HCV infection and of HCC. Cirrhosis is currently the tenth leading cause of death in Africa. There are relatively few studies in Africa, but the prevalence of NAFLD may be around 20%. African regions carry a high share of the global hepatitis B burden. 

The highest incidence and prevalence of HBV is in the African region with Western and Central Africa accounting for 82.8% and 17.2%, respectively, of Africa’s disease burden. In Africa, hepatitis B is reported as the leading cause of viral ALF(Acute Liver Failure). Between 21-27% of HCC cases in Africa are attributable to ALD. The highest ASMR due to alcohol-related cirrhosis was observed in Western SSA (7.3 per 100,000), while the lowest was seen in Southern SSA (2.3 per 100,000). Few countries in Africa have liver transplant capabilities, with only 67 (0.2%) out of 27,692 liver transplants performed globally undertaken in Africa.

Restraints

Factors such as high costs associated with the treatment and stringent regulatory requirements for the approval of new treatments are expected to hamper the market. The higher costs of drugs that are associated with the treatment of various liver diseases affect the affordability for many people and this acts as a restraint to the Middle East and Africa Liver disease treatment market. 

Market Segment Analysis

The Middle East and Africa liver disease treatment market is segmented based on disease type, treatment type, and end-user.

The segment non-alcoholic fatty liver disease accounted for approximately 43.6% of the Middle East and Africa liver disease treatment market share.

The non-alcoholic fatty liver disease segment is expected to hold the largest market share over the forecast period. In this segment, the increasing prevalence and recent treatment approvals would drive this market. 

Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat builds up in your liver. This buildup of fat is not caused by heavy alcohol use. When heavy alcohol use causes fat to build up in the liver, this condition is called alcohol-associated liver disease. Two types of NAFLD are nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). People typically develop one type of NAFLD or the other, although sometimes people with one form are later diagnosed with the other form of NAFLD.

For instance, according to the Journal of Hepatology, the incidence of metabolic dysfunction-associated liver diseases, such as fatty liver disease, is rising rapidly and is likely to contribute to cirrhosis and HCC development in Africa. The estimated prevalence of NAFLD in the African region is 13.5%. In African countries, the prevalence of NAFLD was 9.5% and 4.5% among individuals with or without type 2 diabetes, respectively, in Nigeria, 73% in those with type 2 diabetes in Ethiopia, and 87% in obese or overweight liver clinic patients in Western Cape, South Africa.

Market Segmentation

By Disease Type

• Hepatitis 
• Autoimmune Diseases
• Non-Alcoholic Fatty Liver Disease
• Liver Cancer
• Genetic Disorder
• Others 

By Treatment Type

• Antiviral Drugs  
• Sofosbuvir
• Ombitasvir
• Immunosuppressants
• Vaccines 
• Hepatitis B vaccine
• Hepatitis A vaccine
• Combined hepatitis A and B vaccine
• Immunoglobulins
• Corticosteroids 
• Prednisone
• Targeted Therapy 
• Sorafenib 
• Regorafenib 
• Chemotherapy Drugs 
• Nivoluma
• Pembrolizumab

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Market Competitive Landscape

The major global players in the Middle East and Africa liver disease treatment market include Aspen Holdings, Bayer AG, Adcock Ingram, F. Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, Johnson & Johnson Services Inc., Sanofi, Cipla, and Merck & Co. Inc. among others.

Key Developments

• In May 2024, Pfizer Inc. patented the 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17- β-HSD 13) inhibitors for the treatment of various liver disorders such as hepatocellular carcinoma, biliary cirrhosis, hepatitis B, and hepatitis C viral infections, alcoholic and nonalcoholic fatty liver disease, among others.

Why Purchase the Report?

• To visualize the Middle East and Africa liver disease treatment market segmentation based on disease type, treatment type, and end-user as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of Middle East and Africa liver disease treatment market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.

The Middle East and Africa liver disease treatment market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies